BRIEF — Crescent Biopharma — Potential To Initiate First CR — 001 Phase 3 Study In Early 2028
Oct 15 (Reuters) — Crescent Biopharma, Inc.: Crescent Biopharma - Potential To Initiate First Cr-001 Phase 3 Study In Early 2028 Crescent Biopharma - Multiple Sac-tmt Plus Cr-001 Phase 2 Studies Ongoing In Over 700 Patients; Data Mid-2027 Crescent Biopharma -On Track To Report Initial Monotherapy Data From Ascend In Q1